41 results
424B5
pts2nuj1k4sm ic0
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
392vz6db
23 Mar 22
Prospectus supplement for primary offering
5:14pm
424B5
xzfdzte75g 075n28
17 Nov 21
Prospectus supplement for primary offering
9:02am
424B5
274i25 as3mztvyij996
15 Nov 21
Prospectus supplement for primary offering
5:24pm
8-K
EX-99.1
ub7v43z8 qmm
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
nwyqf4mixv
6 Apr 20
Departure of Directors or Certain Officers
8:30am
S-8
EX-99.1
elxaz64zdyx ev
27 Feb 20
Registration of securities for employees
12:00am